Work

Second Look Lab — Research Brief: NO–cGMP pathway in ME/CFS & Long COVID

Year: 2026

Type: preprint

Abstract: Computational drug-repurposing brief. Three independent screens (genetics, a long COVID ranking, and a literature hidden-link analysis) converge on the NO-sGC-cGMP vascular pathway in ME/CFS and long COVID, and highlight riociguat and nebivolol as untested follow-up candidates to the Charite vericiguat trial. Hypothesis only. Not medical advice. A SHA-256 hash of this PDF (60a68cb498496e31dd527a905fdba8ea3e9c50816c3017f558d990d46358a968) was timestamped with OpenTimestamps on 2026-11-08.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.24078248

Author: Second Look Lab

Language: English

Topic: Long-Term Effects of COVID-19

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

Open Access status: green

OpenAlex ID: W7225649451

Cites:

Cited by:

Related to: